Transcript Field induced Magnetic Nanoparticle Drug Delivery

Field-Induced
Magnetic Nanoparticle
Drug Delivery
BME 273 Group 15
Team Leader : Ashwath Jayagopal (BME, EE, MATH)
Members : Sanjay Athavale (BME) and Amit Parikh (BME)
Advisor : Dr. Dennis Hallahan, Chairman of Radiation Oncology and Professor of
Biomedical Engineering and Radiation Oncology, Vanderbilt University
Dr. Paul King, PE, Associate Professor of Biomedical Engineering, Mechanical
Engineering and Anesthesiology, Vanderbilt University
Project Objectives
•Develop an effective method for site-specific drug delivery to a tumor using the
properties of magnetic nanoparticles
•Design a device that provides the optimum magnetic field effect needed for
delivery of drug-containing particles to an exact location
•Use the device in conjunction with irradiation and biological treatment processes
to enhance delivery
•Reduce problems associated with current treatment methods dramatically
Overview of Magnetic Technology
•Using recently developed methods, medications can be encased to magnetic
nanoparticles
•Given antibody coating, avoids immune reaction, yet lasts in circulation
•Superparamagnetic iron oxide nanoparticles exhibit strong magnetic properties
given an externally applied field
•Can be produced in uniform sizes and properties (Georgia Tech consortium)
•Guided missiles that can deliver to affected area without harming healthy tissue
– enhanced by irradiation of tumor area
Rationale and Market Appeal
•Could potentially be used for treatment of cancer and non-cancer illness
•Since 1990 16 million diagnosed with cancer, 5-year survival rate is 62%
•Current side effects associated with treatment : lower blood counts, flu-like
symptoms, hair loss, swelling, scars and wounds, weight fluctuation, nausea,
diarrhea, healthy cell death
•Magnetic nanoparticle treatment : site-specific administration, duration of dosage
controlled, reduced side effects, more effective treatment
•R&D costs <$2 million, clinical trials <$1 million, procedure <<$4,000, US drug
delivery market estimated worth : $24 billion
(sources : American Cancer Society 2003, Lynne Falk and Chris Iversen BME 273 Design Webpage, Scripps Reports
2001)
Our solution
•Design an electromagnet matrix that precisely
controls nanoparticle drug delivery of
doxorubicin (Upjohn, 1987) to a tumor bearing
mouse
•Irradiate tumor area
•Possibly use biological factors in our design
(TNF, EGF, albumin coat)
•To quantify performance, use fluorescent
tracers to indicate concentration, location, and
dosage duration, as well as magnetometer
Michigan State Univ. 2003,
http://www.pa.msu.edu/~tomanek/patent
s/ffmed/
Obstacles
•Nanoparticle aggregation
•Tumor permeability
•Drug delivery location and
duration
•Imaging of procedure is
challenging
•Type of Electromagnet,
controlling magnetic field
Univ. Central Florida 2003 : http://wwwunix.oit.umass.edu/~nano/NewFiles/Over34_UCFlorida.pdf
Current Achievements
•Have decided on 4 potential designs
•Collaborated with multiple VUMC personnel and received useful feedback on
our design – potential sources of error in design reduced
•Secured facilities, resources (nanoparticles, mice), and funding
•Have established contacts with the Georgia Institute of Technology magnetic
carrier consortium, and Chemicell Gmbh, as well as Duramag and Bunting
Magnetics (electromagnet retailers)
•Have recorded observations on nanoparticles and their properties
Future Objectives
•Conduct experiments on mice tumors using nanoparticles
•Continue consultation with contacts to incorporate the most effective
electromagnet – nanoparticle combination in our design
•Purchase electromagnet, construct a magnetometer, begin constructing prototypes
•Continue research on patents, develop revised IWB and begin designsafe
immediately, obtain feedback on current progress from advisors (King, Hallahan)